Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients with Severe Hypercholesterolemia Not Adequately Controlled with Conventional Lipid-modifying Therapies
To provide patients with severe hypercholesterolemia at risk for subsequent cardiovascular (CV) events and not adequately controlled with currently available lipid-modifying therapy (LMT) access to al...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Aventis recherche & de`veloppement
Update Il y a 4 ans
Long-term safety study in patients included in CLARINET study with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt and for whom the shunt is still in place at one year of age
To determine the safety up to 18 months of age of the extended use of 0.2 mg/kg/day clopidogrel in patients who are included in CLARINET study with cyanotic congenital heart disease palliated with a s...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
Sanofi-Aventis VELOUR : Essai de phase 3 randomisé en double aveugle, comparant l’efficacité d’une chimiothérapie de type FOLFIRI associée ou non à de l’aflibercept chez des patients ayant un cancer colorectal métastatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A multinational, randomized, double-blind study, comparing the efficacy of aflibercept once every 2 weeks versus placebo in patients with metastatic colorectal cancer (MCRC) treated with irinotecan / ...
Country
France
organs
Côlon ou Rectum (colorectal)
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman Max 99 years
Sanofi-Synthelabo Co. Ltd
Update Il y a 4 ans
Comparison of the efficacy and tolerability of drotaverine 80 mg or ibuprofen 400 mg administered alone with their combination for the treatment of primary and secondary dysmenorrhea
A vizsgálat célja annak bizonyítása, hogy a drotaverine 80 mg és az ibuprofen 400 mg kombináció hatékonyabb és ugyanolyan jól-tolerált, mint az ibuprofen 400 mg és a drotaverine 80 mg önmagában.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
An Open-label, randomised, controlled, multi-centre study of the immunogenicity and safety of a booster dose of two different Hepatitis B vaccines to explore the anamnestic immune response in healthy 4 to 7 year-old children previously vaccinated at about 3, 5 and 11 to 13 months of age with either HEXAVAC or INFANRIX-HEXA
Immunogenicity To describe in subjects vaccinated with 3 doses of HEXAVAC or 3 doses of INFANRIX-HEXA during the first two years of life the percentage of subjects with an anti-HBs antibody titre &#...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Study of Sanofi Pasteur's dengue vaccine in Subjects Aged 2 to 45 Years in the Philippines
Safety and reactogenicity Viremia Dengue immune responses and Persistence of antibodies
Country
None
organs
None
Specialty
None
More information
Woman and Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
TCD11379 : Essai de phase 1 en escalade de dose, évaluant la tolérance et la pharmacocinétique de l’ombrabuline (AVE8062) en association avec le bévacizumab, chez des patients ayant une tumeur solide avancée. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est de déterminer la dose la plus adaptée d’ombrabuline à administrer, en association avec le bévacizumab, chez des patients ayant une tumeur solide avancée. Les patients rece...
Country
France
organs
Tumeurs solides
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
A multicenter, randomized, double blind, placebo controlled Phase III study to assess the efficacy of xaliproden in patients with oxaliplatin-induced peripheral sensory neuropathy (PSN) following adjuvant chemotherapy for colon cancer
To assess the effect of xaliproden hydrochloride (xaliproden) 1 mg per oral daily on the rate of complete resolution of PSN at 6 months, following randomization, after the completion of oxaliplatin-ba...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
A Study to Compare Pharmacodynamics and Pharmacokinetics of Insulin Glargine 300 U/mL (Toujeo®) to Insulin Degludec (Tresiba®) Under Steady State in Subjects with Type 1 Diabetes Mellitus (T1DM)
To compare the pharmacodynamic profile of Toujeo with Tresiba in steady state in a euglycemic clamp after 8 days once daily dosing regimen at 2 dose levels in T1DM patients
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
Randomized comparison of a two-month regimen of irbesartan versus enalapril on cardiovascular markers in patients with acute coronary syndrome without ST segment elevation
The main objective of this study is to assess if a two-month regimen of irbesartan in patients hospitalized for acute coronary syndrome without ST segment elevation can reduce inflammation markers (ie...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next